Teva Pharmaceutical continues to grow

There's been much discussion about Big Pharma losing drug sales to generics as patents expire. So what about the generics, have they been gaining?

Teva Pharmaceutical Industries Ltd. (TEVA), the largest generic drug maker in the world, indeed reported today that its top and bottom line improved. Excluding charges related to the $7.46 billion acquisition of generic drug developer Barr Pharmaceuticals, Teva said its net income gained 4 percent compared to the same quarter last year. On a per share basis, Teva earned 71 cents, which was actually down 4 percent from last year due to taxes, dilution and more, beating Reuters estimates of 68 cents per share.